Furosemide ( DrugBank: Furosemide )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
86	Pulmonary arterial hypertension	1

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04706910 (ClinicalTrials.gov)	January 20, 2021	21/12/2020	18F-DOPA II - PET Imaging Optimization	18F-DOPA II - PET Imaging Optimization	Congenital Hyperinsulinism;Neuroblastoma;Parkinson Disease;Lewy Body Disease;Neuroendocrine Tumors;Brain Tumor	Drug: 18F-DOPA;Drug: Furosemide Injection	University of Alberta	NULL	Recruiting	N/A	N/A	All	800	Phase 3	Canada

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05569655 (ClinicalTrials.gov)	April 6, 2021	1/10/2022	Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH	Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With Right Heart Failure Caused by Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension;Randomized Controlled Trial	Drug: Tolvaptan;Drug: Furosemide	Chinese Pulmonary Vascular Disease Research Group	NULL	Recruiting	18 Years	N/A	All	100	N/A	China